Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Vikram Karnani — FY2025 total compensation $1,715,846

Vikram Karnani is President and Chief Executive Officer of Collegium Pharmaceutical, Inc (COLL). The company reported total compensation of $1,715,846 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$875,000
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive plan$835,406
Pension and non-qualified deferred compensation$0
All other compensation$5,440
Total$1,715,846

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Collegium Pharmaceutical, Inc filed April 7, 2026, accession 0001628280-26-024063.

03

Peer context

Peer-group chief executive median$8,418,147
Difference from that median$-6,702,300
Percentile within the disclosed peer group1st
Peers with a disclosed figure6

Medians and percentiles are computed across the peer group Collegium Pharmaceutical, Inc discloses in its own compensation disclosure.

04

The other named executive officers of Collegium Pharmaceutical, Inc

Named executive officerRoleFY2025 total
David DieterExecutive Vice President and General Counsel$3,870,092
Colleen TupperExecutive Vice President and Chief Financial Officer$3,515,055
Scott DreyerExecutive Vice President and Chief Commercial Officer$3,041,212
Shirley KuhlmannFormer Executive Vice President, Chief Administrative Officer, General Counsel and Secretary$2,783,583
Thomas SmithExecutive Vice President and Chief Medical Officer$2,446,008
Vikram Karnani this pagePresident and Chief Executive Officer$1,715,846

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Collegium Pharmaceutical, Inc compensation brief.

05

The company page

Vikram Karnani's compensation sits inside Collegium Pharmaceutical, Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Collegium Pharmaceutical, Inc (COLL) compensation brief